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Key Points
Question
Are there specific antipsychotic combinations that are superior to monotherapies in the maintenance
treatment of schizophrenia?
Findings
This cohort study on 62 250 individuals with schizophrenia with up to 20-year follow-up used withinindividual analysis to minimize selection bias and showed that antipsychotic polypharmacy in general was
associated with slightly lower risk of psychiatric rehospitalization than monotherapy. Clozapine plus
aripiprazole combination was associated with the best outcome, having 14% to 23% lower risk of
rehospitalization than clozapine alone, which was the monotherapy associated with the best outcomes.
Meaning
The findings of this study suggest that certain types of polypharmacy may be associated with fewer
rehospitalizations than monotherapies.

Abstract
Importance
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC6495354/?report=printable
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The effectiveness of antipsychotic polypharmacy in schizophrenia relapse prevention is controversial, and
use of multiple agents is generally believed to impair physical well-being.
Objective
To study the association of specific antipsychotic combinations with psychiatric rehospitalization.
Design, Setting, and Participants
In this nationwide cohort study, the risk of psychiatric rehospitalization was used as a marker for relapse
among 62 250 patients with schizophrenia during the use of 29 different antipsychotic monotherapy and
polypharmacy types between January 1, 1996, and December 31, 2015, in a comprehensive, nationwide
cohort in Finland. We conducted analysis of the data from April 24 to June 15, 2018. Rehospitalization
risks were investigated by using within-individual analyses to minimize selection bias.
Main Outcomes and Measures
Hazard ratio (HR) for psychiatric rehospitalization during use of polypharmacy vs during monotherapy
within the same individual.
Results
In the total cohort, including 62 250 patients, 31 257 individuals (50.2%) were men, and the median age
was 45.6 (interquartile range, 34.6-57.9) years. The clozapine plus aripiprazole combination was
associated with the lowest risk of psychiatric rehospitalization in the total cohort, being superior to
clozapine, the monotherapy associated with the best outcomes, with a difference of 14% (HR, 0.86; 95%
CI, 0.79-0.94) in the analysis including all polypharmacy periods, and 18% in the conservatively defined
polypharmacy analysis excluding periods shorter than 90 days (HR, 0.82; 95% CI, 0.75-0.89; P < .001).
Among patients with their first episode of schizophrenia, these differences between clozapine plus
aripiprazole vs clozapine monotherapy were greater (difference, 22%; HR, 0.78; 95% CI, 0.63-0.96 in the
analysis including all polypharmacy periods, and difference, 23%; HR, 0.77; 95% CI, 0.63-0.95 in the
conservatively defined polypharmacy analysis). At the aggregate level, any antipsychotic polypharmacy
was associated with a 7% to 13% lower risk of psychiatric rehospitalization compared with any
monotherapy (ranging from HR, 0.87; 95% CI, 0.85-0.88, to HR, 0.93; 95% CI, 0.91-0.95; P < .001).
Clozapine was the only monotherapy among the 10 best treatments. Results on all-cause and somatic
hospitalization, mortality, and other sensitivity analyses were in line with the primary outcomes.
Conclusions and Relevance
Combining aripiprazole with clozapine was associated with the lowest risk of rehospitalization, indicating
that certain types of polypharmacy may be feasible in the treatment of schizophrenia. Because add-on
treatments are started when monotherapy is no longer sufficient to control for worsening of symptoms, it is
likely that the effect sizes for polypharmacy are underestimates. Although the results do not indicate that
all types of polypharmacy are beneficial, the current treatment guidelines should modify their categorical
recommendations discouraging all antipsychotic polypharmacy in the maintenance treatment of
schizophrenia.

Introduction
Antipsychotic polypharmacy is used among up to 30% of patients with schizophrenia.1 The use of
antipsychotic polypharmacy has raised concern owing to the lack of evidence for its efficacy and safety as
well as variable justifications and practice patterns.2,3,4,5,6,7 Meta-analyses of randomized clinical trials
(RCTs) have shown mixed results,8,9,10,11,12 possibly because of shortcomings owing to low number of
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC6495354/?report=printable
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participants and lacking separations of high- vs low-quality studies. The most-recent meta-analysis without
these limitations concluded that data from high-quality studies show beneficial outcomes only for negative
symptom reduction with aripiprazole augmentation.12 Short-term symptom reduction, used as the primary
outcome in RCTs, is an important measure for effectiveness of antipsychotic treatment. However,
schizophrenia is a lifelong illness, and long-term outcome, including relapse prevention and avoidance of
adverse physical morbidity and mortality effects owing to long-term antipsychotic load, is an even more
important issue for the patients’ well-being.13,14 Conducting an RCT on these outcomes would require
several thousands of patient-years, which is probably the reason why no such studies have been done.
Observational studies can overcome this problem by using large electronic databases. Results from 1 large
observational study have shown that any antipsychotic polypharmacy was associated with an
approximately 40% lower risk of rehospitalization and death compared with any monotherapy,15 but the
major problem in observational studies is residual confounding related to selection bias. This limitation
can be eliminated by using within-individual analyses in which each patient is used as his or her own
control.16,17,18 To our knowledge, no observational study has been published on the comparative
effectiveness of antipsychotic combinations vs monotherapies using this method. We aimed to study this
issue, using within-individual analyses, in a nationwide cohort including all patients with schizophrenia in
Finland.

Methods
Study Population
This study was based on a cohort of all persons with schizophrenia treated in the inpatient setting during
1972-2014 in Finland, identified from the Hospital Discharge register maintained by the National Institute
of Health and Welfare. Data were also retrieved from the National Prescription register (maintained by
Social Insurance Institution, 1995-2015) and National Death register (1972-2015). The Hospital Discharge
register includes all inpatient hospital stays in Finland, recorded for all residents. The detailed information
on the study population is given in the eMethods in the Supplement. The follow-up started January 1,
1996, for the prevalent cohort and at the first discharge from inpatient care for the incident cases. The
follow-up time ended at death or December 31, 2015, whichever occurred first. We conducted analysis of
the data from April 24 to June 15, 2018.
The research project was approved by the ethics committee of the Finnish National Institute for Health and
Welfare. Further permissions were granted by pertinent institutional authorities at the National Institute for
Health and Welfare of Finland, the Social Insurance Institution of Finland, and Statistics Finland. The
study was registry based and no contact was made with the participants of the study, and therefore
according to Finnish legislation informed consents were not needed.
Exposure
Antipsychotic dispensations were derived from the National Prescription register, defined by Anatomical
Therapeutic Chemical classification code N05A, excluding lithium.19 The register includes reimbursed
drug dispensations for the entire Finnish population but does not include drugs used during hospital stays.
Data on dispensed drug and amount, also recorded in defined daily doses (World Health Organization19),
were used for this study. Drug dispensations were modeled with PRE2DUP modeling, a method used to
define drug use periods (ie, when drug use started and ended).20 The detailed indication of the drug use
modeling is shown in the eMethods in the Supplement.
Outcomes
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Psychiatric rehospitalization (International Classification of Diseases, Tenth Revision codes F20-F29 as
main diagnoses) and all-cause hospitalization were the primary outcome measures. Sensitivity analyses
were conducted among incident (first-episode of schizophrenia) patients and for antipsychotic
polypharmacy periods excluding the first 90 days of overlap. Hospitalization owing to physical illness and
mortality were included as secondary outcomes to take into account that antipsychotic use may have
adverse effects on physical health.
Covariates
The within-individual study design is based on the comparison of different time periods for the same
person. Thus, all time-invariant covariates, such as sex, age, time since illness onset, comorbidities, and
number of previous psychiatric hospitalizations at cohort entry, are controlled for in the design, and only
time-varying covariates are adjusted for in the statistical analysis. Time-varying covariates were the order
of antipsychotic exposures, time since cohort entry, and use of other psychotropic drugs (ie,
antidepressants, benzodiazepines, lithium, mood stabilizers, sedatives). In this study, grouping of
antipsychotics was not identical with the previous study,18 resulting in minimally different hazard ratios
(HRs) for monotherapies.
The traditional Cox proportional hazards regression models (between-individual analysis) were adjusted
for sex, age at cohort entry, year of cohort entry, time since diagnosis, number of prior psychiatric
hospitalizations, comorbidities, and drug use, as described in eTable 1 in the Supplement.
Statistical Analysis
Hospitalization-based outcomes (psychiatric and all-cause hospitalization) were treated as recurrent events
and analyzed with a stratified Cox proportional hazards regression model.16 In this within-individual
design, each patient formed his or her own stratum, and follow-up time was reset to 0 after each outcome
event (eFigure 1 in the Supplement). Persons who had both variation in exposure and experienced an
outcome event during the follow-up contributed to within-individual analysis. The main analysis compared
use of the following drugs in monotherapy and as 2-drug combinations with time when no antipsychotic
was used: oral risperidone, quetiapine, clozapine, olanzapine, aripiprazole, and other oral formulations, as
well as any long-acting injectable agent. These analyses were conducted in the prevalent cohort (including
all patients) and in the incident cohort, including only patients with first-episode, and for both psychiatric
and all-cause hospitalization as an outcome event.
Sensitivity analyses were conducted by censoring the first 90 days from antipsychotic use to retrieve time
of conservatively defined polypharmacy (ie, excluding switches between monotherapies). This censoring
was also conducted for monotherapy periods in an identical way. Also, traditional multivariate-adjusted
Cox proportional hazards regression analyses were conducted for all outcome events, and these models
were adjusted for covariates provided in eTable 1 in the Supplement. The level of statistical significance
was set at P < .0017 according to Bonferroni correction (0.05/29 = .0017).
We used the traditional multivariate-adjusted Cox proportional hazards regression as secondary betweenindividual analyses. In within-individual analysis, only individuals with variation in the exposure
(monotherapy, polypharmacy, no antipsychotic) and outcome (rehospitalization) contributed to the model,
whereas, for between-individual analysis, all patients contributed to the model. The analyses were
conducted using R, version 3.1.1 (R Foundation).

Results
In the total cohort, including 62 250 patients, 31 257 individuals (50.2%) were men, and the median age
was 45.6 (interquartile range, 34.6-57.9) years. The baseline characteristics of the cohort are reported in
the Table. The follow-up time in this study was 20 years or less, with a median time of 14.1 years
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC6495354/?report=printable
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(interquartile range [IQR], 6.9-20.0 years) in the prevalent cohort and 10.1 years (IQR, 5.0-14.3) in the
incident cohort (Table). During the follow-up, 58.8% (n = 36 631) of the prevalent cohort and 57.9% (n =
5045) of the incident cohort were readmitted for psychiatric inpatient care. Concerning rehospitalization
rates after discontinuation of medication, the median time was 211 (IQR, 68-566) days.
Corresponding values for all-cause hospitalization were 86.2% (n = 53 633) of the prevalent cohort and
80.0% (n = 6971) of the incident cohort. A total of 67.2% (n = 41 812) of the patients in the total cohort
and 54.1% (n = 4717) of those in the incident cohort used antipsychotic polypharmacy during the followup, and 57.5% (n = 35 793) of the prevalent cohort and 41.6% (n = 3627) of the incident cohort were
exposed to antipsychotic polypharmacy for at least 90 days. Median doses of specific antipsychotics used
in the prevalent and incident cohorts are described in eTable 2 in the Supplement.
The overall view on the risks of psychiatric rehospitalization for specific treatments in the total cohort are
presented in Figure 1 and eTable 3 in the Supplement. The corresponding results using monotherapies as
the reference are shown in Figure 2 and Figure 3. The lowest risk of rehospitalization was observed for
clozapine plus aripiprazole polypharmacy (Figure 2), being 14% lower (HR, 0.86; 95% CI, 0.79-0.94; P
< .001) than that for clozapine, the monotherapy associated with the best outcomes. Among individuals
who used clozapine both as monotherapy and polypharmacy, the mean clozapine dose was 426 mg/d
during monotherapy and 399 mg/d during polypharmacy. When other specific polypharmacy
combinations, excluding the composite group of any long-acting injectable agents, were compared with the
better antipsychotic component of each combination, no combination was statistically superior to
monotherapy when strict Bonferroni correction was applied. eTable 4 in the Supplement reports the
outcome noted when any other antipsychotic was added to aripiprazole, clozapine, olanzapine, quetiapine,
and risperidone.
The risk of psychiatric hospitalization, all-cause hospitalization, or death was not decreased significantly
by adding any miscellaneous antipsychotic (most of those other than aripiprazole) to clozapine. However,
including any other agent with quetiapine, which had the worst monotherapy response, resulted in a better
outcome. At an aggregate level, the risk of psychiatric rehospitalization was 7% lower during any
polypharmacy than any monotherapy period without censoring the first 90-day periods of antipsychotic
treatment (HR, 0.93; 95% CI, 0.91-0.95; P < .001). The HR for all-cause hospitalization was 0.91 (95% CI,
0.89-0.92; P < .001), and for death, 0.76 (95% CI, 0.73-0.79; P < .001).
eFigure 2 and eTable 5 in the Supplement provide the results for psychiatric rehospitalization when the
first 90 days were censored from all treatment periods to eliminate potential artificial polypharmacy
periods that may have occurred when one antipsychotic was switched to another. The superiority of
clozapine plus aripiprazole (which had HR, 0.55; 95% CI, 0.51-0.61 vs no antipsychotic) over clozapine
monotherapy (which had HR, 0.68; 95% CI, 0.66-0.70 vs no antipsychotic) was even greater (difference,
18%; HR, 0.82; 95% CI, 0.75-0.89; P < .001) in this conservatively defined polypharmacy analysis. In this
analysis, the risk of rehospitalization was 13% lower during any polypharmacy than any monotherapy
treatment (HR, 0.87; 95% CI, 0.85-0.88; P < .001).
The risk of all-cause hospitalization is shown in eFigure 3 and eTable 6 in the Supplement. Again,
clozapine plus aripiprazole was associated with a substantially better outcome than any other treatment.
Figure 4 and eTable 7 in the Supplement show the results for the first-episode group with no antipsychotic
use as reference. The superiority of the clozapine plus aripiprazole combination over any other treatments
was even more robust than in the total cohort. When clozapine, the monotherapy associated with the best
outcomes, was used as reference, the HR for clozapine plus aripiprazole combination was 0.78 (95% CI,
0.63-0.96) in the analysis including all polypharmacy periods, and 0.77 (95% CI, 0.63-0.95) in
conservatively defined polypharmacy analysis. The risk of hospitalization owing to physical illness is
given in eFigure 4 and eTable 8 in the Supplement, showing the lowest risks for polypharmacy and longacting injectable agent monotherapy.
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC6495354/?report=printable

6/17

3/18/2020

Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia

The results for all-cause mortality are presented in eFigure 5 and eTable 9 in the Supplement. Among 29
different treatments, all monotherapies except clozapine were among the 10 worst, although all treatments
were associated with a 50% or more lower risk of death compared with no antipsychotic use. The results
for psychiatric hospitalizations with between-individual analysis including all patients, as well as also
those without polypharmacy or hospitalizations, are presented in eFigure 6, eFigure 7, eTable 10, and
eTable 11 in the Supplement. Clozapine and clozapine plus aripiprazole were again among the most
favorable treatments.

Discussion
To our knowledge, this is the first study on the long-term use of antipsychotic polypharmacy in
schizophrenia. It is nearly impossible to conduct an RCT including tens of thousands of patient-years to
achieve sufficient statistical power. Therefore, observational studies are the only way to investigate longterm comparative outcomes. The major shortcoming in observational studies is selection bias, because
treatments are not chosen on a random basis. In this study, we used within-individual analyses in which
each patient is used as his or her own control to minimize selection bias. We observed that when treatment
for the same patient was switched back and forth between monotherapy and polypharmacy, the use of
aripiprazole plus clozapine was associated with a 14% to 23% lower risk of psychiatric or all-cause
hospitalization compared with clozapine monotherapy. Clozapine was the monotherapy associated with the
best outcomes, and clozapine plus aripiprazole was associated with significantly better outcome than any
other antipsychotic treatment, either as monotherapy or polypharmacy. Quetiapine was the least successful
monotherapy, as has been observed also in previous Swedish and Finnish studies.17,18
One possible explanation for the superiority of polypharmacy is that, in the real-world setting, treatment
adherence is poor,21,22,23 and, if the patient has prescriptions for 2 antipsychotics, he or she may use at
least 1 of them. However, other data suggest that the more medications or doses used, the more difficult it
is for patients to adhere to the treatment regimen.22 Regarding the clozapine plus aripiprazole
combination, the clozapine dose was only slightly lower during polypharmacy than during monotherapy,
which suggests that reduction of the dose was not the major explanation for the better outcome. However,
it is plausible that the different types of receptor profiles result in beneficial effects. For example, in a
meta-analysis, addition of the partial dopamine D2 receptor agonist aripiprazole to clozapine therapy
improved negative symptoms and reduced several adverse effects, such as weight gain and increased
prolactin level, whereas a combination of 2 dopamine D2 antagonists was associated with greater prolactin
elevation but less insomnia.12 Such a reduced adverse effect burden could also increase adherence.
The mean daily doses of risperidone and quetiapine were low in our cohort, showing what happens in a
total, nationwide cohort of patients with schizophrenia. It is probable that the prescribed doses had been
higher, but the observed consumed doses (calculated on the basis of successively filled prescriptions in
pharmacies) indicated the doses that patients actually used, and it is plausible that they titrated the doses to
the level that they could tolerate. Therefore, patients may be willing to use 2 antipsychotics in relatively
low doses but refuse to use high or moderate doses of monotherapy even though the total defined daily
dose would be lower during monotherapy. Therefore, it would be misleading to presume that effectiveness
(efficacy plus tolerability) would correlate with the total antipsychotic dose expressed as defined daily
doses or chlorpromazine equivalents.
Our results revealed that, in general, antipsychotic polypharmacy was associated with an approximately
10% lower relative risk of psychiatric rehospitalization (corresponding to an approximately 6% lower
absolute risk with an approximately 60% rehospitalization rate in the cohort) compared with antipsychotic
monotherapy, translating into a number needed to treat of 10 to 20, which is generally considered clinically
meaningful. This effect size is larger than the effect size of statin treatments for the prevention of
cardiovascular incidents.24 To reach statistical significance for a result of this magnitude, the minimum
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC6495354/?report=printable
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number of patients to compare 2 groups of treatments is approximately 1000. This sample size requirement
for a long-term study is probably a major reason why RCTs are difficult to conduct to answer questions
about the relative effectiveness of several active treatments in the maintenance management of
schizophrenia.
In addition, secondary analyses on hospitalization owing to physical illness and mortality showed better
outcomes for antipsychotic combinations than for monotherapy. Because add-on treatments are started
when monotherapy is no longer sufficient to control for worsening of symptoms, it is likely that the effect
sizes for the superiority of antipsychotic polypharmacy over monotherapy are underestimates. The results
obtained with 90-day omission in each treatment period (conservatively defined polypharmacy analysis
excluding switch periods) were more robust than those without 90-day omission and are probably more
accurate estimates on the results of polypharmacy. The results from between-individual analyses, including
all patients, showed similar rank order as within-individual analyses. This finding indicates that the
clozapine plus aripiprazole combination is associated with the best outcome in the entire population of
Finnish patients with schizophrenia. The results may generalize to other high-income countries with a
majority white population but not necessarily to other societies. Only 1 other study has compared multiple
antipsychotic combinations in relapse prevention.15 Our results are in line with those of Katona et al,15
showing a lower risk of rehospitalization during antipsychotic polypharmacy compared with monotherapy.
However, our effect sizes were smaller, which may be explained by use of within-individual analysis,
which minimizes selection bias.
Our results on mortality are in line with those of previous cohort studies, showing lower mortality during
antipsychotic polypharmacy than monotherapy.15,25,26 Two small studies have reported a positive
correlation between antipsychotic polypharmacy and mortality: one investigated the maximum number of
concomitant antipsychotics used during a 10-year follow-up (n = 88)27 and the other studied the number of
antipsychotics used (n = 99) at baseline of a 17-year follow-up.28 Because these studies were based on case
records, their results may reveal associations between mortality and the number of antipsychotic
prescriptions given to patients several years before death rather than actual past or current use based on
filling of prescriptions. Our outcomes did not include functioning or quality of life, but these outcomes are
reflected to some extent in mortality and psychiatric and somatic hospitalization rates.
Strengths and Limitations
This study has both strengths and limitations. We included all hospital-treated patients in Finland with up
to 20-year follow-up and used within-individual analysis to minimize selection bias. In addition, timevarying covariates, such as time since cohort entry and order of exposures (ie, switch from monotherapy to
polypharmacy vs switch from polypharmacy to monotherapy), were adjusted in the analysis. One
limitation is that our main outcomes were risk of rehospitalization owing to psychiatric or somatic reasons,
and our database did not include information on symptoms, reason for polypharmacy, quality of life, and
level of functioning. We did not have information on concomitant psychosocial treatments, but it is
unlikely that there would be any systematic differences between polypharmacy and monotherapy in this
regard. In addition, clozapine and long-acting injectable agent treatments require regular contact with
health care staff, which may be associated with better outcomes, but it is unlikely that the increased contact
would explain the difference between polypharmacy and monotherapy. Another limitation of the study was
that the results may generalize to only high-income countries with a majority white population. An
additional limitation was protopathic-type bias (ie, the fact that add-on treatments are started when
symptoms become worse). Therefore, the effect sizes for polypharmacy are probably underestimated.

Conclusions
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Our results suggest that patients had the lowest risk of psychiatric or all-cause hospitalization when they
received combination therapy with clozapine plus aripiprazole, which was significantly superior to
clozapine, which was the monotherapy associated with the best outcomes. These results indicate that
rational antipsychotic polypharmacy seems to be feasible by using 2 particular antipsychotics with
different types of receptor profiles.
Current treatment guidelines state that antipsychotic monotherapy should be preferred and polypharmacy
should be avoided if possible. These recommendations reflect the recent evidence in high-quality studies
on the acute-phase treatment. However, results from our study suggest that antipsychotic polypharmacy
may be superior to monotherapy for maintenance treatment, which has not been examined with RCTs.
Therefore, it should be acknowledged that statements about a preferential use of antipsychotic
monotherapy for maintenance treatment of schizophrenia lack evidence, and that currently available
evidence—although gathered with few nonrandomized cohort studies that have their own limitations—
indicates the opposite. Therefore, the current treatment guidelines should modify their categorical
recommendations discouraging all antipsychotic polypharmacy in the maintenance treatment of
schizophrenia.
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Table.
Characteristics of the Prevalent and Incident Cohorts and Hospitalizations During Follow-up
Characteristic

Cohort, No. (%)
Prevalent (n = 62 250) Incident (n = 8719)

Age at baseline, y
≤24

5368 (8.6)

1844 (21.2)

25-34

10 748 (17.3)

2297 (26.3)

35-44

13 996 (22.5)

1417(16.3)

45-54

13 767 (22.1)

1266 (14.5)

55-64

8833 (14.2)

763 (8.8)

≥65

9538 (15.3)

1132 (13.0)

Median age (IQR), y

45.6 (34.6-57.9)

36.2 (26.2-52.3)

Men

31 257 (50.2)

4898 (56.2)

0

8617 (13.8)

1748 (20.0)

1

7948 (12.8)

1443 (16.6)

2-4

17 194 (27.6)

2603 (29.9)

5-8

12 423 (20.0)

1520 (17.4)

≥9

16 068 (25.8)

1405 (16.1)

No. of all-cause hospitalizations per person, median (IQR)

4 (1-9)

3 (1-6)

0

25 619 (41.2)

3674 (42.1)

1

10 233 (16.4)

1615 (18.5)

2-4

13 490 (21.7)

1980 (22.7)

5-8

6273 (10.1)

805 (9.2)

≥9

6635 (10.7)

645 (7.4)

No. of all-cause hospitalizations

No. of psychiatric hospitalizations

No. of psychiatric hospitalizations per person, median (IQR) 1 (0-4)

1 (0-3)

Follow-up time, median (IQR), y

10.1 (5.0-14.3)

14.1 (6.9-20.0)

Open in a separate window
Abbreviation: IQR, interquartile range.
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Figure 1.

Open in a separate window
Risk of Psychiatric Rehospitalization During Specific Treatments Compared With No Antipsychotic Use in the
Prevalent Cohort (Within-Individual Analysis)
HR indicates hazard ratio; LAI, long-acting injectable agent. Orange markers indicate monotherapies.
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Figure 2.

Open in a separate window
Risk of Psychiatric Rehospitalization in the Total Cohort, Compared With Clozapine, Aripiprazole, and
Olanzapine Monotherapy (Within-Individual Analysis)
HR indicates hazard ratio; LAI, long-acting injectable agent.

https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC6495354/?report=printable

15/17

3/18/2020

Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia

Figure 3.

Open in a separate window
Risk of Psychiatric Rehospitalization in the Total Cohort, Compared With Risperidone, Quetiapine, and Any
Long-Acting Injectable Agent (LAI) Monotherapy (Within-Individual Analysis)
HR indicates hazard ratio; LAI, long-acting injectable agent.
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Figure 4.

Open in a separate window
Risk of Psychiatric Hospitalization During Specific Treatments Compared With No Antipsychotic Use in the
Incident Cohort (Within-Individual Analysis)
HR indicates hazard ratio. LAI, long-acting injectable agent. Orange markers indicate monotherapies.
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